One Test
For All
Cancers
Simple Blood Test to Screen
for Early Indicators of Cancer
One Test for All Cancers
The HrC Test: One Test for All Cancers
The revolutionary HrC technology is the result of dedicated research by a team of Indian scientists at Epigeneres Biotech in Mumbai, led by the late Dr. Vinay Kumar Tripathi. Their pioneering work began while evaluating a drug interacting with a cancer pathway, leading to a remarkable discovery: the drug was specifically affecting a small, previously unnoticed population of cells.
This serendipitous observation prompted deeper investigation, which unveiled a critical epigenetic change occurring within stem cells. This alteration effectively transformed them into cancer stem cells. These newly formed cancer stem cells were then observed to generate more cancer cells, which ultimately coalesce to form a discernible tumour.
A pivotal realisation for the scientists was that these crucial cancer stem cells must be circulating within the bloodstream. However, detecting them presented a significant challenge due to their incredibly small size and extreme rarity, making up only about 0.025% of all blood cells. This scarcity meant that without precise knowledge of their existence and characteristics, these cells were often overlooked or even destroyed, leading to the erroneous conclusion of their absence.
Following the successful identification of these elusive stem cells in the blood, the next essential step involved developing methods to effectively isolate and enrich them. This crucial process was necessary to prepare the samples for detailed analysis using advanced Next Generation Sequencing (NGS) technology.
First Universal Blood Test for Cancer
Through their ongoing research, the scientists uncovered a profound commonality: it appears that all types of cancer initiate through the same fundamental mechanism. This ground-breaking insight holds the potential to truly revolutionise cancer diagnostics, paving the way for what could be the first universal blood test for cancer. To date, HrC technology has already demonstrated its effectiveness in detecting over 60 different types of cancer, a very promising indicator of its broad applicability.
A truly unique advantage of HrC is its ability to provide a clear result for individuals who are not currently at risk of cancer. When someone is identified as being in a “safe zone,” it means there is no immediate likelihood of them developing cancer within the next 12 months. This capability makes HrC an exceptional candidate for annual cancer screenings. It can either reassure individuals that they remain in the “safe zone” or, if a risk is detected, enable cancer to be caught at a very early stage, often Stage 1 or even earlier.
The research team also discovered that these cancer stem cells begin to mobilise into the bloodstream as soon as any pathology occurs within an organ. Critically, in the context of cancer, this can happen a substantial 12 to 18 months before a tumour even develops and becomes detectable by conventional methods. Currently, no other known technology offers such an early detection window for cancer. Furthermore, HrC has consistently demonstrated high sensitivity in detecting cancer across all disease stages, from Stage 1 through to Stage 4.
Key Benefits of the HrC Test
The HrC technology offers several significant advantages in cancer diagnostics:
- Potential for Pan-Cancer Detection: By leveraging a common cancer initiation pathway, HrC shows promise for detecting over 60 cancer types, potentially becoming a universal screening tool.
- “Safe Zone” Confirmation: It provides a unique “no risk” reading, indicating no likely cancer development within 12 months, which is invaluable for proactive health monitoring.
- Unprecedented Early Detection: HrC can identify cancer-related cellular changes 12-18 months before a tumour forms, offering an unmatched early warning system.
- Consistent Sensitivity: The technology consistently detects cancer with high accuracy across all stages of the disease.
- Ideal for Annual Screening: Its ability to spot early-stage cancer or confirm a risk-free status makes it highly suitable for regular preventative health checks.
Gold Edison Award Winner, 2025
